Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  15.00 1.37% 1,110.00 62,742 16:35:01
Bid Price Offer Price High Price Low Price Open Price
1,070.00 1,110.00 1,090.00 1,090.00 1,090.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.39 12.63 20.00 55.5 541
Last Trade Time Trade Type Trade Size Trade Price Currency
17:50:24 O 672 1,100.11 GBX

Ergomed (ERGO) Latest News

More Ergomed News
Ergomed Investors    Ergomed Takeover Rumours
Smart Money!
ERGO is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BLACKROCK THROGMORTON TRUST PLC 2.10% 2021-02-28
 BLACKROCK SMALLER COMPANIES TRUST PLC 1.90% 2021-02-28
 JPMORGAN SMALLER COMPANIES INVESTMENT TRUST PLC 3.60% 2021-02-28

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
12/4/202122:51Ergomed PLC871
14/1/202010:16Stephen Stamp, CFO of Ergomed (ERGO)2

Add a New Thread

Ergomed (ERGO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:50:241,100.116727,392.74O
16:07:531,110.001,00011,100.00O
15:49:271,100.005976,567.00O
15:48:541,100.005976,567.00O
15:35:011,110.006,00066,600.00UT
View all Ergomed trades in real-time

Ergomed (ERGO) Top Chat Posts

DateSubject
12/4/2021
09:20
Ergomed Daily Update: Ergomed Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ERGO. The last closing price for Ergomed was 1,095p.
Ergomed Plc has a 4 week average price of 1,065p and a 12 week average price of 930p.
The 1 year high share price is 1,295p while the 1 year low share price is currently 362.50p.
There are currently 48,746,109 shares in issue and the average daily traded volume is 149,794 shares. The market capitalisation of Ergomed Plc is £541,081,809.90.
12/4/2021
22:51
piedro: 12 Apr 2021 MedSource and PSR Orphan Experts rebrand to Ergomed Today, we are delighted to share the exciting news that following the successful integration of both PSR Orphan Experts and MedSource we will be aligning all our CRO businesses under the Ergomed name. hTTps://www.ergomedplc.com/medsource-and-psr-orphan-experts-rebrand-to-ergomed/
08/4/2021
12:36
frankwhite: Low volume today abnormally affecting the share price, classic sign of a buying opp if ever I saw one! So I topped up.
27/3/2021
18:11
maddox: Richard Barfield, CFO Ergomed on Shares Magazine - Shares Investor Evening https://www.youtube.com/watch?v=EZWCR4ksK5o Excellent presentation. Very strong results – two acquisitions, strong growth, US market presence is paying-off, strong cash generation based on high cash conversion (98%) and a huge order book (up 55% under-pinning future growth). ERGO has led the development of digitisation of service delivery which has of course been thrust forward with Covid-19. It’s likely that ERGO will finance further acquisitions funded out of its own resources. In this growing market with high quality returns – this is good use of its cash. So forward p/e of 40 is not cheap but fair value in consideration of a fast organic growth and internally funded acquired growth. Regards Maddox
14/12/2020
14:59
apad: One of my concerns is the revenue per worker. At about £88k this is low and I assume the workers are expensive. Capitalisation/Revenue is not bad at 7 years. Early days for a Profitability/Revenue metric. I compared ERGO with AFX as they both offer a service and are similar mkt caps. ERGO has ten times the employees and three times the number of jobs on offer. AFX has £287k of revenue per worker and ERGO £88k. Not an entirely equal comparison (but what are). I'm not posting this to slag ERGO off as I am attracted to a service industry in this sector. I'd be interested in counterarguments as I'm a bit of a scaredy cat. apad
11/12/2020
10:22
bramble13: Don't think for one moment you have missed out on this company, this is just the beginning of a long financial gain for investors. Last year was a transformational year, the chairman said so,and he knows best.He also said this will be a year Matterialy ahead of expectations.We can look forward to many years of a good dividend yield.This is going to a high growth company for long term holdersDon't be frightened of the high share price.
13/10/2020
10:40
maddox: I conceptualise it as a firm's value versus share price. Fundamentals provide insight into value only; whereas technical analysis is seeking insight into the market dynamic between buyers and sellers that determine the current share price direction. So, by using both analyses you should get a more complete picture of the opportunity.
27/9/2020
21:27
sharesoc: For those interested, we are running a ShareSoc Webinar with Ergomed on the 6 October 2020. You can register here: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-ergomed-ergo-6-october-2020/
22/9/2020
15:44
grabster: Reported in Shares magazine this afternoon: Market & Company News: Ergomed profit up 44% as Covid-related trials boost business 22 September 2020, 14:03Source - SMW Pharmaceutical services company Ergomed posted a 44% rise in first-half profit after it won new business, including in Covid-19-related trials, and substantially boosted revenue in North America. The company also said it was planning a capital reduction, in light of its financial progress 'and to increase its ability to pay dividends, to facilitate any prospective buy back of shares and for any other general corporate purposes'. Pre-tax profit for the six months through June increased to £6.0m, up from £4.1m on-year, as revenue climbed 15% to £40.4m, including by 79% in North America. The company did not declare an interim dividend. 'Ergomed has delivered exceptional progress both operationally and financially during the first half of 2020, continuing to demonstrate our ability to drive sustained growth through a clear focus on our service model strategy,' chief executive Miroslav Reljanovic said. 'We responded robustly to the challenges of the Covid-19 pandemic, with strong revenue and profit growth, a growing order book and sales momentum across the business.' 'We expect to see this momentum continue into the second half of the year, driven by further demand for our PV and CRO services.' 'We will continue to invest for organic growth and efficiency with a disciplined approach to strategic acquisition opportunities and are firmly positioned to realise our potential as a leading global provider of specialist services to the pharmaceutical industry.' At 2:03pm: (LON:ERGO) Ergomed Plc share price was +85p at 775p
29/1/2020
07:09
epicsurf: Ergomed 2019 Trading Update 2019 EBITDA ahead of market expectations Outlook underpinned by strong order book and Ashfield Pharmacovigilance acquisition Guildford, UK - 29 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces a trading update for the year ended 31 December 2019. The Company will provide further details of its performance for 2019 in its preliminary results announcement expected in March 2020.  Summary - EBITDA ahead of expectations Following the positive results for the first half of the year reported in September 2019, Ergomed continued to deliver strong year on year top-line growth and financial performance across the business and expects revenue for the year ended 31 December 2019 to be in line with current market expectations and EBITDA for the year ended 31 December 2019 to be ahead of current market expectations. Strong trading and forward-looking order book The positive trading performance seen in both Ergomed's Clinical Research Organisation ("CRO") and its Pharmacovigilance ("PV") businesses during the first six months of the year has continued through to the year end and resulted in a strong order book at the start of 2020. Revenues for 2019 are expected to be in line with expectations at approximately £68 million, an increase of 26% over prior year (2018: £54.1 million), with CRO revenues increasing 23% from £26.6 million to £32.6 million and PV revenues increasing 29% from £27.5 million to £35.4 million. The strong revenues and continued focus on profitability in 2019 are expected to result in adjusted EBITDA[1] ahead of current market expectations. The combined CRO and PV order book at the end of 2019 is expected to be approximately £125 million, up by 15% over prior year (2018: £109 million). The Company continued to be debt-free at the year end with cash and equivalent balances over £14 million (2018: £5.2 million). Current year outlook The Company's outlook for 2020 is positive, bolstered by the strong order book and the acquisition of Ashfield Pharmacovigilance ("APV") which closed on 10 January 2020, thereby providing almost a full year of additional revenues with scope for increased penetration in the enlarged client base with extended geographies and services. In 2019 Ergomed benefited from a one-off revenue and EBITDA uplift arising from change orders and project completions, announced on 16 May 2019, which is not expected to recur in 2020. In the longer term, the acquisition of APV will strengthen Ergomed's presence globally, benefitting both the CRO and PV businesses.  Continued strengthening of the Board Ergomed has continued to bolster its executive team and Board of Directors with the recent appointment of Lewis Cameron as Chief Operating Officer and to the Board. Lewis was formerly Head of Global Clinical Development at Covance, the CRO division of Laboratory Corporation Holdings of America and was previously instrumental in driving growth and the integration of acquired businesses at Chiltern International. Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: "2019 has been a transformational year for Ergomed. The momentum seen in the first half has continued and the business has performed ahead of market expectations for the full year. Our recent acquisition of Ashfield Pharmacovigilance marks a further major step in our strategy, establishing a broader platform in the US and a substantially enlarged client base. With a robust financial position, strong order book and strengthened leadership team, we are firmly positioned to deliver on the promise of becoming a leading mid-tier pharmaceutical services specialist with a global presence."
24/6/2019
20:04
timbo003: I had assumed that the recent perkiness in the Ergo share price was due to them shifting away from the co-development model and just focusing on the pharmaceutical services parts of the business. Unfortunately I couldn't get to the AGM earlier this year, if I had gone, I had lots of questions about that. If they end up making the transition completely, I wonder if they are contemplating selling the future royalty streams from the current co-development portfolio? I suspect there would be plenty of potential buyers.
Ergomed share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 22:53:34